<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0E15EB87-2459-4FD4-BFCC-19208921CCC6"><gtr:id>0E15EB87-2459-4FD4-BFCC-19208921CCC6</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>McAdoo</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901997"><gtr:id>DC07A663-6421-475B-9E0C-34FB43188E50</gtr:id><gtr:title>The importance of Spleen tyrosine kinase (Syk) as a potential therapeutic target in glomerulonephritis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0901997</gtr:grantReference><gtr:abstractText>Antibody-mediated diseases are those caused by the body?s immune system targeting our own organs. When this occurs in the kidneys it causes inflammation, called glomerulonephritis. This is a common cause of kidney failure. Current treatments for this condition are not always effective and may have severe side-effects. Better and safer treatment is needed.
We have shown that a drug called R788 is extremely effective in treating animals with immune-mediated glomerulonephritis. R788 is also effective in treating humans with other forms of immune-mediated disease, such as rheumatoid arthritis. I would like to investigate whether this drug would be a useful and safe treatment for glomerulonephritis in humans.
I will achieve this by comparing the effects of R788 on white blood cells and kidney cells taken from humans and animals with glomerulonephritis. I aim to establish if the drug?s target molecule is present in human cells, and if so, whether it is active in reducing levels of inflammation and the antibodies responsible for autoimmunity. This information may provide the basis for a future clinical trial of R788 in humans with glomerulonephritis.
I will undertake this research along with other doctors from the Imperial College Kidney and Transplant Institute in London.</gtr:abstractText><gtr:technicalSummary>Antibody-mediated glomerulonephritis (GN) is a major cause of end stage renal disease. Current treatments for GN are non-specific, not always effective, and associated with significant toxicity. More effective treatment is needed.
We have shown that R788, an oral prodrug of R407, a small molecule inhibitor of spleen tyrosine kinase (Syk) is remarkably effective in both preventing and treating established disease in an antibody-dependent animal model of crescentic GN that is characterized by early macrophage infiltration into glomeruli (nephrotoxic nephritis, NTN). Syk is an intracellular tyrosine kinase that has an established role in immunoreceptor signaling. There is also accumulating evidence that Syk is involved in post-receptor signaling of various cytokines including TNFa, IFNa and IL-1a. I wish to establish the precise role of Syk in NTN and the mechanisms by which Syk inhibition acts, with a view to developing a rationale for inhibiting Syk in the treatment of human GN.
The proposed study incorporates a detailed in vitro analysis of the effects of Syk inhibition on cultured rat and human cell lines (macrophages and mesangial cells) and nephritic rat glomeruli ex vivo, using a variety of techniques including standard and cell-based ELISA, western blot and microsphere cytokine assays. siRNA techniques will be employed to determine the specificity of R406 in inhibiting Syk dependent pathways.
I will also examine the effect of Syk inhibition on autoantibody production in vivo, using an animal model of glomerulonephritis that relies on antibody production following immunization with the a3 chain of type IV collagen (experimental autoimmune glomerulonephritis).
The proposal also includes a study of human material. The presence of activated Syk and its downstream targets will be assessed in biopsy specimens from patients with GN using immunohistochemistry (IHC), allowing me to identify those patients in whom Syk inhibition should be a therapeutic target. I will determine the pattern of urinary and tissue cytokine expression in these patients, using microsphere cytokine assays of urine samples and real time PCR of tissue obtained from biopsies by laser capture microdissection. By correlation with the IHC findings, I may be able to identify surrogate markers of Syk activation in tissue or urine that could be used clinically to identify patients who would benefit from Syk inhibition.
I expect that the results of these studies should clarify the potential role of Syk in human GN, and may form the basis of future clinical trials using Syk inhibition as a therapeutic strategy.</gtr:technicalSummary><gtr:fund><gtr:end>2014-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-08-31</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>250197</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Lecturer Start-Up Grant</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Academy of Medical Sciences (AMS)</gtr:fundingOrg><gtr:id>BAA2E9A7-6BC9-402F-9C3D-A491D878BD94</gtr:id><gtr:outcomeId>56b13d4f7c6ef8.84354860</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Vasculitis UK Research Grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Vasculitis UK</gtr:fundingOrg><gtr:id>28A83D42-EC44-46FA-B094-DFBA3DAF1B4F</gtr:id><gtr:outcomeId>56b13de41353d8.81394866</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>50675A68-1B78-41AA-B7A8-5B5EB605A7C4</gtr:id><gtr:title>Predicting Outcome in Patients with Anti-GBM Glomerulonephritis.</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63f74fae497aa3351f1bb2fa52f3fb09"><gtr:id>63f74fae497aa3351f1bb2fa52f3fb09</gtr:id><gtr:otherNames>van Daalen EE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>5aaa632d883f58.81320868</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACA66A1E-84D8-4CE6-982A-BE6E645E47A3</gtr:id><gtr:title>Clinical characteristics and outcomes of HIV-associated immune complex kidney disease.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c926053cd3c7f247fa364994945f7609"><gtr:id>c926053cd3c7f247fa364994945f7609</gtr:id><gtr:otherNames>Booth JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>56b13c92dda1e5.25511612</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7352E71-22ED-49E8-B351-833B834B1485</gtr:id><gtr:title>Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/146ac95ad5d2ed8fb8539d89caeebad3"><gtr:id>146ac95ad5d2ed8fb8539d89caeebad3</gtr:id><gtr:otherNames>McAdoo SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>5aaa632f82ecc0.87994476</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8010F481-5C91-43F4-A3F9-F4D0A5D07126</gtr:id><gtr:title>Immunodeficiency-associated renal Burkitt lymphoma.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f13f9b0cbf80f22ba2465601b46b276b"><gtr:id>f13f9b0cbf80f22ba2465601b46b276b</gtr:id><gtr:otherNames>White W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>56b13c93844317.09282916</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C300DC1A-2C26-4589-A949-4DA22F84C867</gtr:id><gtr:title>Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/146ac95ad5d2ed8fb8539d89caeebad3"><gtr:id>146ac95ad5d2ed8fb8539d89caeebad3</gtr:id><gtr:otherNames>McAdoo SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>5aaa632d3ac316.06990122</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BFB3311-339C-4036-866C-79DB37478A05</gtr:id><gtr:title>Focal necrotizing and crescentic glomerulonephritis in patients with normal serum creatinine</gtr:title><gtr:parentPublicationTitle>La Presse M?dicale</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7eacea70879da1567e32419fbab98c5d"><gtr:id>7eacea70879da1567e32419fbab98c5d</gtr:id><gtr:otherNames>Mcadoo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5464b9f91b1711.27431169</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32E22BE2-BF11-4D16-AE4A-35F2915CA640</gtr:id><gtr:title>Spleen tyrosine kinase (SYK) inhibition in experimental autoimmune glomerulonephritis (EAG)</gtr:title><gtr:parentPublicationTitle>La Presse M?dicale</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7eacea70879da1567e32419fbab98c5d"><gtr:id>7eacea70879da1567e32419fbab98c5d</gtr:id><gtr:otherNames>Mcadoo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5464b9f8e93b61.01923712</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2BAB8C5-E4A9-409D-81AD-F40FD7DFC671</gtr:id><gtr:title>Proteinase-3 antineutrophil cytoplasm antibody positivity in patients without primary systemic vasculitis.</gtr:title><gtr:parentPublicationTitle>Journal of clinical rheumatology : practical reports on rheumatic &amp; musculoskeletal diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/146ac95ad5d2ed8fb8539d89caeebad3"><gtr:id>146ac95ad5d2ed8fb8539d89caeebad3</gtr:id><gtr:otherNames>McAdoo SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1076-1608</gtr:issn><gtr:outcomeId>pm_16483_23_23047533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60C375CA-9201-4A11-8F33-BFDC952FBBEF</gtr:id><gtr:title>Spleen Tyrosine Kinase: A Crucial Player and Potential Therapeutic Target in Renal Disease.</gtr:title><gtr:parentPublicationTitle>Nephron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f15795e0db039c536ac1dd74a553046"><gtr:id>7f15795e0db039c536ac1dd74a553046</gtr:id><gtr:otherNames>Ma TK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1660-8151</gtr:issn><gtr:outcomeId>585d6134393b12.15964019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A95766F-A139-4ABC-8938-893707B3C8EA</gtr:id><gtr:title>Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b040e32b3d20f649e7b18385a90bfd30"><gtr:id>b040e32b3d20f649e7b18385a90bfd30</gtr:id><gtr:otherNames>Kim MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_16483_23_22956578</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B401F0B5-05B3-46BA-B7CB-4A2657BEC907</gtr:id><gtr:title>Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f15795e0db039c536ac1dd74a553046"><gtr:id>7f15795e0db039c536ac1dd74a553046</gtr:id><gtr:otherNames>Ma TK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>5a578bfbc44d55.62864721</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B13CE6A5-A8C6-4C7F-9905-564BE41F717D</gtr:id><gtr:title>Fostamatinib Disodium.</gtr:title><gtr:parentPublicationTitle>Drugs of the future</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/146ac95ad5d2ed8fb8539d89caeebad3"><gtr:id>146ac95ad5d2ed8fb8539d89caeebad3</gtr:id><gtr:otherNames>McAdoo SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0377-8282</gtr:issn><gtr:outcomeId>ZDu9Qxx8qpD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F249B017-AE53-4421-A2CB-24F55014FF78</gtr:id><gtr:title>Long-term outcome in patients with both ANCA and GBM positivity</gtr:title><gtr:parentPublicationTitle>La Presse M?dicale</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59c3fa2af7a41fd165c4140e7260dbfd"><gtr:id>59c3fa2af7a41fd165c4140e7260dbfd</gtr:id><gtr:otherNames>Tanna A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5464b9f8c1a0b2.10535163</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>348A25CD-AC6C-4A3A-93C6-35925FB67A28</gtr:id><gtr:title>Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/146ac95ad5d2ed8fb8539d89caeebad3"><gtr:id>146ac95ad5d2ed8fb8539d89caeebad3</gtr:id><gtr:otherNames>McAdoo SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>5464b9f93cc735.85749720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18D621A0-066E-43FD-A118-5B9F358EC025</gtr:id><gtr:title>Spleen Tyrosine Kinase - A Novel Target in Autoimmunity</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e3507127c7fcef49038142c2ec3b3f0"><gtr:id>1e3507127c7fcef49038142c2ec3b3f0</gtr:id><gtr:otherNames>Stephen P McAdoo, Frederick W. K. Tam</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>978-953-51-0152-9</gtr:isbn><gtr:outcomeId>iRHCeP83dLd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60AE43CC-D330-43BA-94AF-DF5930452710</gtr:id><gtr:title>Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival,&amp;nbsp;frequency of relapse, and outcomes compared to single-seropositive patients.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/146ac95ad5d2ed8fb8539d89caeebad3"><gtr:id>146ac95ad5d2ed8fb8539d89caeebad3</gtr:id><gtr:otherNames>McAdoo SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>5aaa632e2199b1.71778399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5B087F9-16FC-4D35-92FB-5B98CFAB416A</gtr:id><gtr:title>Is there a role for TNFa blockade in ANCA-associated vasculitis and glomerulonephritis?</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/146ac95ad5d2ed8fb8539d89caeebad3"><gtr:id>146ac95ad5d2ed8fb8539d89caeebad3</gtr:id><gtr:otherNames>McAdoo SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>5aaa632dca14f1.20476364</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>624943B0-9C05-4E05-A98C-D0E9C39874B1</gtr:id><gtr:title>Anti-Glomerular Basement Membrane Disease.</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/146ac95ad5d2ed8fb8539d89caeebad3"><gtr:id>146ac95ad5d2ed8fb8539d89caeebad3</gtr:id><gtr:otherNames>McAdoo SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>5aaa632f156c06.77056290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1B2F4FB-942F-471F-9D77-B6FEF8991A9A</gtr:id><gtr:title>Bacterial endocarditis associated with proteinase 3 anti-neutrophil cytoplasm antibody.</gtr:title><gtr:parentPublicationTitle>NDT plus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/146ac95ad5d2ed8fb8539d89caeebad3"><gtr:id>146ac95ad5d2ed8fb8539d89caeebad3</gtr:id><gtr:otherNames>McAdoo SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1753-0784</gtr:issn><gtr:outcomeId>h1Z8a12Cwmz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63BD2AD7-984B-4919-B73A-0787157E1AFB</gtr:id><gtr:title>Acute renal failure in diabetes: looking beyond diabetic retinopathy</gtr:title><gtr:parentPublicationTitle>Clinical Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87f294dd83f1ccdeff71991ca0eb0a78"><gtr:id>87f294dd83f1ccdeff71991ca0eb0a78</gtr:id><gtr:otherNames>McAdoo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>5464b9f8737193.70359978</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABD7268D-DDE2-4640-A099-28426214C361</gtr:id><gtr:title>L46. Novel forms of clinical vasculitis: anti-GBM vasculitis (Goodpasture's disease).</gtr:title><gtr:parentPublicationTitle>Presse medicale (Paris, France : 1983)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/146ac95ad5d2ed8fb8539d89caeebad3"><gtr:id>146ac95ad5d2ed8fb8539d89caeebad3</gtr:id><gtr:otherNames>McAdoo SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0755-4982</gtr:issn><gtr:outcomeId>pm_16483_23_23477716</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05ED6BBF-0940-48E6-8968-5BCD88A2046D</gtr:id><gtr:title>Renal tubular disease in the era of combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d426d779c840a490da55f26dbb7b7238"><gtr:id>d426d779c840a490da55f26dbb7b7238</gtr:id><gtr:otherNames>Hamzah L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56b13c934faf92.53460199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E29806B1-AE0D-427E-81AF-BE318B8934B3</gtr:id><gtr:title>Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis: Impact on Localized and Nonlocalized Disease.</gtr:title><gtr:parentPublicationTitle>Ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b40bf79a86e72a938f2e0985f2ceff87"><gtr:id>b40bf79a86e72a938f2e0985f2ceff87</gtr:id><gtr:otherNames>Joshi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0161-6420</gtr:issn><gtr:outcomeId>56b13c93213d70.38964645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E4F1B26-6562-4F37-A46E-6C89541CEC94</gtr:id><gtr:title>Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/146ac95ad5d2ed8fb8539d89caeebad3"><gtr:id>146ac95ad5d2ed8fb8539d89caeebad3</gtr:id><gtr:otherNames>McAdoo SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>5675e021e80c9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA207DFC-754F-450E-8C27-D88D456881E8</gtr:id><gtr:title>BCAT1 controls metabolic reprogramming in activated human macrophages and is associated with inflammatory diseases.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a381e1e74ba3c39cffaa39ff0aba0c48"><gtr:id>a381e1e74ba3c39cffaa39ff0aba0c48</gtr:id><gtr:otherNames>Papathanassiu AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5aaa632eb45900.74380712</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C2A7661-ACAF-4F50-99D1-729D32611F98</gtr:id><gtr:title>Necrotizing and crescentic glomerulonephritis presenting with preserved renal function in patients with underlying multisystem autoimmune disease: a retrospective case series.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/146ac95ad5d2ed8fb8539d89caeebad3"><gtr:id>146ac95ad5d2ed8fb8539d89caeebad3</gtr:id><gtr:otherNames>McAdoo SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>56b13c93ac3a58.23630157</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FEB6CAA-36F5-4058-83AC-A5BC5F304DB5</gtr:id><gtr:title>Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/146ac95ad5d2ed8fb8539d89caeebad3"><gtr:id>146ac95ad5d2ed8fb8539d89caeebad3</gtr:id><gtr:otherNames>McAdoo SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>5464b9f960c371.56238856</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02A0882E-B4DC-4395-AD5F-09A0AD09C213</gtr:id><gtr:title>Clustering of Anti-GBM Disease: Clues to an Environmental Trigger?</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/146ac95ad5d2ed8fb8539d89caeebad3"><gtr:id>146ac95ad5d2ed8fb8539d89caeebad3</gtr:id><gtr:otherNames>McAdoo SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>5aaa632f4b9826.39833802</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA29221E-4280-4096-9C4D-CD875588DFF5</gtr:id><gtr:title>Experimental crescentic glomerulonephritis: a new bicongenic rat model.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31dae1a71fe75df54587677cd8a4b30e"><gtr:id>31dae1a71fe75df54587677cd8a4b30e</gtr:id><gtr:otherNames>D'Souza Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn><gtr:outcomeId>pm_16483_23_24046355</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901997</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>